Pierre Queiroz de Oliveira is an associate in the Intellectual Property Practice Group of Pepper Hamilton LLP, resident in the Pittsburgh office. Dr. Queiroz de Oliveira concentrates his practice in intellectual property, primarily on intellectual property transactions and counseling, with a substantial portion of his work directed to patent preparation and prosecution, due diligence, and licensing matters.
Dr. Queiroz de Oliveira has extensive basic science experience and holds a Ph.D. in molecular pharmacology from the University of Pittsburgh School of Medicine. His research focused on the development of novel therapeutic agents for the treatment of cancer and the regulation of the mammalian cell cycle in hypoxic tumors. During his tenure at the University of Pittsburgh, Dr. Queiroz de Oliveira was selected as a Fellow in molecular pharmacology. His scientific and technological experience include pharmacology, pharmaceuticals and drug development, molecular biology, biochemistry and organic chemistry.
Prior to joining Pepper, Dr. Queiroz de Oliveira was an executive associate at the Pittsburgh Life Science Greenhouse, a life science company formation and capital investment firm. Dr. Queiroz de Oliveira focused on the therapeutics, diagnostics and medical device segments, assisting early stage companies with business development, fundraising and business, commercial and regulatory strategy.
Dr. Queiroz de Oliveira has been published in a number of peer-reviewed journals and his research has been presented at numerous national meetings. His publications and speaking engagements include:
Dr. Queiroz de Oliveira received his J.D. from the Duquesne University School of Law in 2014. Dr. Queiroz de Oliveira received his Ph.D. from the University of Pittsburgh in molecular pharmacology in 2009 and an M.S. degree in pharmacology with honors from the University of Bath in 2002.
- “Hypoxia-Mediated Regulation of Cdc25A Phosphatase by p21 and miR-21” (co-author), Cell Cycle, 2009 Oct 1; 8(19):3157-64
- “An Allosteric Inhibitor of Dusp6, Identified From a Zebrafish Chemical Screen, Expands Cardiac Progenitors and Heart Size” (co-author), Nature Chemical Biology, 2009 Sep; 5(9):680-7
- “Supression of Cdc25A by Hypoxia Required the Cell Cycle Inhibitor p21,” San Diego, CA, April 11-16, 2008
- “Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non-Small Cell Lung Cancer” (co-author), Molecular Pharmacology, 2007; 72(3):769-79
- “Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma” (co-author), Neoplasia, 2006; 8(11): 949-955
- “Novel Benzofuran Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1” (co-author), Bioorg Med Chem, 2006; 14(16):5643-50
- “Ad-IRF-1 Induces Apoptosis in Esophageal Adenocarcinoma” (co-author), Neoplasia, 2006; 8(1):31-7
- “Altered Trafficking of Fas and Subsequent Resistance to Fas-Mediated Apoptosis Occurs by a Wild-Type p53 Independent Mechanism in Esophageal Adenocarcinoma” (co-author), Journal of Surgical Research, 2005; 123(2):302-11
- “The HGF Receptor c-Met is Overexpressed in Esophageal Adenocarcinoma” (co-author), Neoplasia, 2005; 7(1):75-84
- “Restoration of IRF-1 Expression Induces Cell Death in Esophageal Adenocarcinoma Cells,” Digestive Diseases Week, New Orleans, LA, May 15-20, 2004.
Dr. Queiroz de Oliveira is fluent in English, French and Portuguese.